| 22582 | EHRBABE | Babesia and Anaplasma Smear | Anaplasma phagocytophilum, Ehrlichia phagocytophilum, Babesia microti, Giemsa stain | | | 25525 | BABGSO | Babesia microti IgG Antibodies, Serum (BABG) | | | | 25230 | BABNAT | Babesia microti, Nucleic Acid Test | Babesia PCR, Babesiosis PCR | | | 22343 | BABE | Babesia Smear | Babesia microti, Giemsa Stain | | | 26122 | MISC | Bacterial Culture, Cystic Fibrosis with Antimicrobial Susceptibilities (CFRCS) | | | | 26493 | BARBUSO | Barbiturates Confirmation, Random, Urine (BARBU) | Amobarbital (Amytal), Amytal (Amobarbital), Barbita (Phenobarbital), Barbiturates, Barbs, Luminal (Phenobarbital), Nembutal (Pentobarbital), Pentobarbital (Nembutal), Phenobarbital, Secobarbital (Seconal), Seconal (Secobarbital), Solfoton (Phenobarbital), Butalbital (Fiorinal) | | | 22345 | BAR | Barbiturates, Urine | Amobarbital, Amytal, Phenobarbital, Luminal, Nembutal, Pentobarbital. Secobarbital, Seconal, Solfoton , Phenobarbital, Butalbital, Fiorinal | | | 25412 | BARTPAN | Bartonella Ab Panel, IgG & IgM (BART) | Bartonella henselae Abs, IgG/IgM; Bartonella quintana, IgG/IgM; Cat Scratch Disease, Bartonellosis, BART | | | 26208 | BCLLSO | B-Cell IGH Hypermutation Analysis (BCLL) | BCLL
IGVH
IGHV
Next Gen Sequencing Test
Somatic mutation (or Hypermutation)
CLL prognosis | | | 26451 | BALLMSO | B-Cell Lymphoblastic Leukemia Monitoring, Minimal Residual Disease Detection, Flow Cytometry, Varies (BALLM) | Acute Minimal Residual Disease, ALL-MRD, B-ALL MRD, B-cell ALL MRD | | | 25628 | BLYMFSO | B-Cell Lymphoma Tissue, FISH (BLYM) | BLYM
BCL2 (18q21) rearrangement
BCL6 (3q27) rearrangement
Burkitt lymphoma
Burkitt-like lymphoma
CCND2
Diffuse Large Cell Lymphoma/"Double Hit"
Follicular lymphoma
Large BCL with IRF4 rearranged
MALT (18q21) rearrangement
MALT lymphoma
Mantle Cell Lymphoma (MCL)
MYC (8q24.1) rearrangement
MYC/Kappa
MYC/Lambda
Splenic Marginal Zone Lymphoma
t(11;14) (q13;q32) - CCND1/IGH
t(11;18) (q21;q21) - BIRC3/MALT1
t(14;18) (q32;q21) - IGH/MALT1
t(14;18)(q32;q21) - IGH/BCL2
t(2;8)(p12;q24) - IGK/MYC
t(8;14) (q24.1;q32) - MYC/IGH
t(8;22) (q24.1;q11.2) - MYC/IGL
IRF4
DUSP22
TNFRSF14
1p36 TI BLYMFSO | This test does not include a pathology consultation. If a pathology consultation is desired, PATHC / Pathology Consultation should be ordered and the appropriate fluorescence in situ hybridization (FISH) test will be ordered and performed at an additional charge. Mayo Hematopathology Consultants are involved in both the pre-analytic (tissue adequacy and probe selection, when applicable) and post-analytic (interpretation of FISH results in context of specific case, when applicable) phases.
This assay detects chromosome abnormalities observed in paraffin-embedded tissue samples of patients with B-cell lymphoma. If a blood or bone marrow specimen is submitted, the test will be canceled and BLPMF / B-Cell Lymphoma, Specified FISH, Varies will be added and performed as the appropriate test.
If either the break-apart MYC or the MYC/IGH D-FISH probe sets are requested in isolation, both probe sets will be performed concurrently to optimize the detection of MYC rearrangements.
| | 25401 | BCRAMSO | BCR/ABL, p210, RT-PCR(BCRAB) | Acute lymphoblastic leukemia (ALL)
Acute myeloid leukemia (AML)
B lymphoblastic leukemia (B-ALL)
T lymphoblastic leukemia (T-ALL)
BCR-ABL1
BCR ABL
BCR/ABL
Chronic myelogenous leukemia (CML)
Philadelphia chromosome, Ph bone marrow/blood
t(9;22)
Tyrosine kinase inhibitor (TKI) therapy monitoring, PCR | | | 25411 | BCRADSO | BCR/ABL-1 RNA-Qual Diagnostic (BADX) | Philadelphia chromosome Ph bone marrow/blood
Acute lymphoblastic leukemia (ALL)
Acute myeloid leukemia (AML)
BCR-ABL1
BCR ABL
BCR/ABL
B lymphoblastic leukemia (B-ALL)
Chronic myelogenous leukemia (CML)
Chronic myeloid leukemia
T lymphoblastic leukemia (T-ALL)
t(9;22) | This test is only qualitative and should not be used for routine monitoring (ie, quantitative mRNA level). Monitoring of most patients with chronic myeloid leukemia (CML) should be performed using BCRAB / BCR/ABL, p210, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Chronic Myelogenous Leukemia (CML), Varies. Monitoring of patients known to carry a p190 fusion should be performed using BA190 / BCR/ABL, p190, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Assay, Varies. | | 25546 | BC190SO | BCR/ABL1, p190, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Assay, Varies (BA190) | Philadelphia chromosome, Ph bone marrow/blood
Acute lymphoblastic leukemia (ALL)
Acute myeloid leukemia (AML)
B lymphoblastic leukemia (B-ALL)
BCR ABL
BCR/ABL
BCR-ABL1
T lymphoblastic leukemia (T-ALL)
t(9;22) | | | 26479 | BAKDMSO | BCR/ABL1, Tyrosine Kinase Inhibitor Resistance, Kinase Domain Mutation Screen, Sanger Sequencing, Varies (BAKDM) | E255K, E355G, F317L, F369V, G250E, H396R, M244V, M351T, Q252H, T315I, Y253F, Y253H, T315A, V299L, Tyrosine kinase inhibitor (TKI), Kinase domain mutation, ABL, Imatinib resistance, Chronic myeloid leukemia, Chronic myelogenous leukemia (CML), BCR-ABL1, BCR/ABL, BCR ABL, Acute lymphoblastic leukemia (ALL) | | | 22346 | BENZ | Benzodiazepines, Urine | Clonazepam, Temazepam, Diazepam, Chlordiazepoxide, Alprazolam, Flunitrazepam, Flurazepam, Nordiazepam, Chlorazepate, Lorazepam, Xanax, Librium, Valium, Ativan, Serax, Restoril, Date Rape Drug, 7-Aminoflunitrazepam, Roofies, Rohypnol | | | 25092 | CO-BENZ | Benzodiazepines, Urine, Confirm Only by LCMS/MS | Clonazepam, Temazepam, Diazepam, Chlordiazepoxide, Alprazolam, Flunitrazepam, Flurazepam, Nordiazepam, Chlorazepate, Lorazepam, Xanax, Librium, Valium, Ativan, Serax, Restoril, Date Rape Drug, 7-Aminoflunitrazepam, Roofies, Rohypnol | | | 26319 | B2IGA | Beta 2 Glycoprotein 1, IgA | Anti-Phospholipid Antibodies, Antiphospholipid Antibodies, Antiphospholipid syndrome, APS, anti-B2-GP1 antibodies, Beta 2 glycoprotein, Beta-2 glycoprotein, Beta-2 GP1, systemic lupus erythematosus, SLE | | | 26320 | B2IGG | Beta 2 Glycoprotein 1, IgG | Anti-Phospholipid Antibodies, Antiphospholipid Antibodies, Antiphospholipid syndrome, APS, anti-B2-GP1 antibodies, Beta 2 glycoprotein, Beta-2 glycoprotein, Beta-2 GP1, systemic lupus erythematosus, SLE | | | 26321 | B2IGM | Beta 2 Glycoprotein 1, IgM | Anti-Phospholipid Antibodies, Antiphospholipid Antibodies, Antiphospholipid syndrome, APS, anti-B2-GP1 antibodies, Beta 2 glycoprotein, Beta-2 glycoprotein, Beta-2 GP1, systemic lupus erythematosus, SLE | | | 22347 | B2M | Beta-2 Microglobulin | B2M, B2MICRO
| | | 26449 | B2MRUSO | Beta-2 Microglobulin, Random, Urine (B2MU) | B2MRUSO, U B2MRUSO, Beta-2 Microglobulin, Urine (FB2MU), Beta-2 Microglobulin, Urine (B2MU), Beta 2 Microglobulin Test, Beta-2 Microglobulin, Urine, B2M, (Beta-2 Microglobulin) Urine | | | 24970 | BCTXSO | Beta-Crosslaps (Beta-CTx), Serum (CTX) | B-CTx, Beta CrossLaps, Beta-CTx, C-Telopeptide, C-terminal collagen crosslinks, Carboxy terminal collagen crosslinks, CTx | | | 22242 | BOH | Beta-Hydroxybutyrate | Hydroxybutyrate, Ketones, 3-hydroxybutyrate
| | | 22244 | CO2 | Bicarbonate | HCO3, CO2, Total CO2
| | | 24984 | BACIDSO | Bile Acids, Total Serum (BILEA) | Bile Salts Total
Bile Acids, Total, Serum (BILEA) | | | 26446 | UBILALSO | Bile Alcohols, Urine | URINARY BILE ALCOHOL 5b-CHOLESTANE-3a,7a,12a,23S,25-PENTOL, TOTAL | | | 22246 | BILE-U | Bile, Urine | Bilirubin, Urine | | | 26537 | BILAO | Biliary Tract Malignancy, FISH (BILAO) | | | | 22248 | DBIL | Bilirubin, Direct Only | DBIL, Conjugated Bilirubin, Fractionated Bilirubin
| | | 22249 | NBILI | Bilirubin, Neonatal | NBili, Neonatal Bilirubin
| Total Bilirubin, Direct Bilirubin
Indirect Bilirubin will be calculated | | 22250 | TBIL | Bilirubin, Total Only | TBil, Total Bilirubin
| | | 22251 | TBIL-O | Bilirubin, Total, Other Body Fluids | Body Fluid Total Bilirubin | | | 23318 | BIOTESO | Bioavailable Testosterone, Total and Free (TTFB) | Androgens; Bioavailable Testosterone; NonSex Hormone Binding Globulin (SHBG); Testosterone Group; Testosterone, Total Only, Serum
| Testosterone, Total Testosterone, Free Testosterone, Bioavailable | | 22252 | BIOTSSO | Biotinidase, Serum (BIOTS) | Biotin-amide amidohydrolase, Biotinidase deficiency, BTD | | | 26335 | PBKQNSO | BK Virus DNA Detection and Quantification, Plasma (PBKQN) | BK viral load BK virus by PCR BK virus DNA quant BKV by PCR BKV DNA quant BKV viral load BK Virus PCR, Qnt, Plasma | | | 26489 | UBKQNSO | BK Virus DNA Detection and Quantification, Random, Urine (UBKQN) | BK viral load, BK virus by PCR, BK virus DNA quant, BKV by PCR, BKV DNA quant, BKV viral load | | | 26343 | BLASTSO | Blastomyces Antibody, Enzyme Immunoassay, Serum (BLAST) | Blastomycosis, Fungal Serology | | | 26173 | BLCAGSO | Blastomyces Quantitative Antigen, CSF and BAL (316) | Blastomyces Quant Ag, CSF and BF (316) FL BLCAGSO | | | 25016 | BLSAGSO | Blastomyces Quantitative Antigen, Serum (316) | Blastomyces Dermatitidis QNT AG | | | 25581 | BLUAGSO | Blastomyces Quantitative Antigen, Urine (316) | Blastomyces Dermatitidis QNT AG U BLUAGSO | | | 26100 | CHR2NIC | BLIPO, Glucose and Nicotine | Concert Health, CHR | Includes GLU, BLIPO (Total Cholesterol, HDL Cholesterol, Triglyceride, calculated LDL cholesterol and NONHDL Cholesterol), and NICTS (Nicotine and Metabolites). | | 22256 | ABGH | Blood Gases and Hemoglobin, Arterial | Art. Blood Gas w/Hgb | Panel includes Blood Gas (pH, partial pressure of carbon dioxide pCO2, partial pressure of oxygen pO2, bicarbonate HCO3, base excess BE, O2 Saturation) and Hemoglobin results. | | 22257 | VBGH | Blood Gases and Hemoglobin, Venous | Venous Bld Gases w/Hgb | Panel includes Blood Gas (pH, partial pressure of carbon dioxide pCO2, partial pressure of oxygen pO2, base excess BE, O2 Saturation, calculated HCO3-Marshfield Only), and Hemoglobin | | 26528 | CBGNAK | Blood Gases and Na/K, Capillary | Blood Gas, Cap. w/ Sodium, Potassium
| Panel includes Blood Gas (pH, partial pressure of carbon dioxide pCO2, partial pressure of oxygen pO2, bicarbonate HCO3, base excess BE, O2 Saturation), Sodium, and Potassium.
| | 22258 | ABGL | Blood Gases and NA/K/IC, Arterial | Blood Gas, Art. w/ Sodium, Potassium, Ionized Calcium | Panel includes Blood Gas (pH, partial pressure of carbon dioxide pCO2, partial pressure of oxygen pO2, bicarbonate HCO3, base excess BE, O2 Saturation) and Sodium, Potassium, and Ionized Calcium | | 22259 | CBGL | Blood Gases and Na/K/Ic, Capillary | Blood Gas, Cap. w/ Sodium, Potassium, Ionized Calcium
| Panel includes Blood Gas (pH, partial pressure of carbon dioxide pCO2, partial pressure of oxygen pO2, bicarbonate HCO3, base excess BE, O2 Saturation), Sodium, Potassium, and Ionized calcium | | 22260 | VBGL | Blood Gases and Na/K/Ic, Venous | Ven.Bld.Gases & Na/K/Ion.Ca | Panel includes Blood Gas (pH, partial pressure of carbon dioxide pCO2, partial pressure of oxygen pO2, base excess BE, O2 Saturation, calculated HCO3-Marshfield Only), Sodium, Potassium, and Ionized calcium | | 22261 | ABG | Blood Gases, Arterial | Art.Blood Gas, ABG, PCO2, PO2 | Panel includes Blood Gas (pH, partial pressure of carbon dioxide pCO2, partial pressure of oxygen pO2, bicarbonate HCO3, base excess BE, O2 Saturation) | | 22262 | CBG | Blood Gases, Capillary | CBG, Capillary Blood Gases
| Panel includes Blood Gas (pH, partial pressure of carbon dioxide pCO2, partial pressure of oxygen pO2, bicarbonate HCO3, base excess BE, O2 Saturation) | | 22265 | VBGNAK | Blood Gases, Na/K, Venous | Venous Bld, Gases & Na/K | Panel includes Blood Gas (pH, partial pressure of carbon dioxide pCO2, partial pressure of oxygen pO2, base excess BE, O2 Saturation, calculated HCO3-Marshfield Only), Sodium, and Potassium | | 22264 | VBGLH | Blood Gases, Na/K/Ic and Hemoglobin, Venous | Ven.Bld.Gases & Na/K/Ion.Ca w/Hgb | Panel includes Blood Gas (pH, partial pressure of carbon dioxide pCO2, partial pressure of oxygen pO2, base excess BE, O2 Saturation calculated HCO3-Marshfield Only), Sodium, Potassium, Ionized calcium, and Hemoglobin | | 22263 | ABGLH | Blood Gases, NA/K/IC, AND Hemoglobin, Arterial | Blood gas with Hgb, Sodium, Potassium and Ionized Calcium | Panel includes Blood Gas (pH, partial pressure of carbon dioxide pCO2, partial pressure of oxygen pO2, bicarbonate HCO3, base excess BE, O2 Saturation) and Sodium, Potassium, Ionized Calcium, and Hemoglobin results. | | 22266 | UABG | Blood Gases, Umbilical Cord Arterial | Cord Gas, Arterial | Panel includes Blood Gas (pH, partial pressure of carbon dioxide pCO2, partial pressure of oxygen pO2, base excess BE) | | 22267 | UVBG | Blood Gases, Umbilical Cord Venous | Cord Gas, Venous | Panel includes Blood Gas (pH, partial pressure of carbon dioxide pCO2, partial pressure of oxygen pO2, base excess BE) | | 22268 | VBG | Blood Gases, Venous | Venous Blood Gases, VBG | Panel includes Blood Gas (pH, partial pressure of carbon dioxide pCO2, partial pressure of oxygen pO2, base excess BE, O2 Saturation, calculated HCO3-Marshfield Only) | | 22269 | ABORH | Blood Typing, ABO and RH | ABO Grouping, ABO/RH, Type and Rh, ABO/RH Typing, BB - Blood Type, ABO & Rh
| | | 26547 | U HGB | Blood, Urine | hemoglobin urine, qualitative
| Hemoglobin dipstick and Microscopic RBC
| | 26459 | COGBFSO | B-Lymphoblastic Leukemia/Lymphoma, Children's Oncology Group Enrollment Testing, FISH (COGBF) | +4,+10,+17 17p- (17p deletion) or TP53 9p- (9p deletion) or CDKN2A or p16 ABL1 (9q34) rearrangement ABL2 (1q25) rearrangement BCR-ABL1 like ALL CRLF2 (Xp22.33) or (Yp11.32) rearrangement Hyperdiploidy iAMP21 IGH (14q32) rearrangement JAK2 (9p24.1) rearrangement MLL or KMT2A (11q23) rearrangement MYC (8q24.1) rearrangement P2RY8 (Xp22.33) or (Yp11.32) rearrangement PDGFRB (5q33) rearrangement IKZF1 deletion Ph-like ALL t(1;19)(q23;p13.3) - PBX1/TCF3 t(10;11)(p12;q23) - MLLT10/MLL or AF10/MLL t(11;19)(q23;p13.1) - MLL/ELL t(11;19)(q23;p13.3) - MLL/MLLT1 or MLL/ENL t(12;21)(p13;q22) - TEL/AML1 or ETV6/RUNX1 t(4;11)(q21;q23) - AFF1/MLL or AF4/MLL t(6;11)(q27;q23) - MLLT4/MLL or AF6/MLL t(9;11)(p22;q23) - MLLT3/MLL or AF9/MLL t(X;14)(p22.3;q32) - CRLF2/IGH Hypodiploid/pseudo-hyperdiploid Hypotriploid/Near-Triploid Philadelphia-like ALL t(9;22)(9q34;q11.2) - BCR/ABL1 t(Y;14)(p11.32;q32) - CRLF2/IGH 12p13 rearrangement, ETV6 Children's Oncology Group, COG | The FISH panel includes testing for the following abnormalities using the fluorescence in situ hybridization (FISH) probes listed: +9/9p-, CDKN2A/D9Z1 t(9;22) BCR/ABL1 11q23 rearrangement, MLL (KMT2A) break-apart -17/17p-, TP53/D17Z1 t(1;19)(q23;p13), PBX1/TCF3 Hyperdiploidy, +4,+10,+17: D4Z1/D10Z1/D17Z1 t(12;21)(p13;q22), ETV6/RUNX1 fusion and iAMP21 14q32 rearrangement, IGH break-apart t(Xp22.33;var) or t(Yp11.32;var), P2RY8 rearrangement t(Xp22.33;var) or t(Yp11.32;var), CRLF2 rearrangement 8q24.1 rearrangement, MYC break-apart If the FISH panel demonstrates normal or nonclassical abnormalities, BALPF / B-Cell Acute Lymphoblastic Leukemia/Lymphoma (ALL), FISH, Pediatric Varies panel will be performed. The Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL)panel includes testing for the following kinase activating chromosome abnormalities, using the FISH probes listed below as well as IKZF1 deletion, which often accompanies Ph-like ALL: 1q25 rearrangement, ABL2 break-apart 5q33 rearrangement, PDGFRB break-apart 9p24.1 rearrangement, JAK2 break-apart 9q34 rearrangement, ABL1 break-apart 7p-, IKZF1/CEP7 When an MLL (KMT2A) rearrangement is identified, reflex testing will be performed to identify the translocation partner. Probes include identification of: t(4;11)(q21;q23) AFF1/MLL t(6;11)(q27;q23) MLLT4(AFDN)/MLL t(9;11)(p22;q23) MLLT3/MLL t(10;11)(p12;q23) MLLT10/MLL t(11;19)(q23;p13.1) MLL/ELL t(11;19)(q23;p13.3) MLL/MLLT1 When an IGH and/or CRLF2 rearrangement is identified, reflex testing will be performed using the CRLF2/IGH fusion probe set to identify a potential t(X;14)(p22.33;q32) or t(Y;14)(p11.32;q32) cryptic translocation. In the absence of BCR/ABL1 fusion, when an extra ABL1 signal is identified, reflex testing will be performed using the ABL1 break-apart probe set to evaluate for the presence or absence of an ABL1 rearrangement. In the absence of ETV6/RUNX1 fusion, when an extra ETV6 signal is identified, reflex testing will be performed using the ETV6 break-apart probe set to evaluate for the presence or absence of an ETV6 rearrangement. If a MYC rearrangement is identified, both the BCL2 and BCL6 probe sets will be performed. | | 25460 | BFCC | Body Fluid Cell Count | Cell Count Body Fluid, BF Cell Ct
| Total Nucleated Cell Count (WBC), Red Blood Cell Count | | 22415 | BFCC/D | Body Fluid Cell Count and Manual Differential (Not CSF) | Cell Count and Differential, Body Fluid, BFD Cell Ct + Diff | Total Nucleated Cell Count (WBC), Red Blood Cell Count, Percent neutrophils, lymphocytes, monocytes, eosinophils, and basophils and any abnormal nucleated cells present including blasts and nucleated red blood cells. | | 25463 | BAP | Bone Alkaline Phosphatase | Bone-specific Alkaline phosphatase, Ostase | | | 22381 | B.M. | Bone Marrow Differential | Bone Marrow Biopsy, Aspirate
| | | 23165 | BORDPCR | Bordetella by PCR | Pertussis PCR, Whooping Cough by PCR, Parapertussis PCR | | | 25560 | BRAFDSO | BRAF V600E/V600K Somatic Mutation Analysis, Tumor (BRAFD) | Anaplastic thyroid carcinoma
BRAF
BRAF mutation
BRAFD
Brain cancer
Circulating tumor cells
Circulating tumor DNA
CNS tumor
Colon cancer
Colorectal cancer
Craniopharyngioma
Erdheim-Chester disease
Glioma
Hairy Cell leukemia
Histiocytic lesion
Liquid biopsy
Lung cancer
Melanoma
Papillary thyroid carcinoma
V600E
V600K | Slide review, BRAF Mutation Analysis | | 23094 | CA2729 | Breast Cancer Antigen (CA 27.29) | Biomira Truquant BR, Breast Cancer Tumor Markers, Breast Carcinoma, Cancer Antigen 27.29 , (CA 27.29), MAM 6, Milk Mucin, CA 27-29 | | | 22383 | BCA | Breast Cancer Antigen 15-3 | Breast Ca Ag 15-3 (BCA) | | | 26138 | BRBPSSO | Broad Range Bacterial PCR and Sequencing, Varies(BRBPS) | 16S rRNA gene sequencing
Bacterial sequencing
Broad range
Broad-range
16S
Broad
Mycobacteria
Mycobacterial
Ribosomal RNA
rRNA
Sequencing
Next Generation Sequencing
NGS | If polymerase chain reaction (PCR) testing is negative, no sequencing is performed, and the test is resulted as negative. If PCR testing is positive, sequencing is performed. Strong positive results are first submitted to Sanger sequencing, which can yield results in as few as 4 days. Weak positive results, or Sanger sequencing results that are mixed, are submitted to next-generation sequencing (ie, targeted metagenomics testing). | | 22384 | BRUCSO | Brucella Abortus Serology (SS02002) | Brucellosis, Undulant fever, B. abortus, Brucellosis Agglutinins | Quantitative direct agglutination procedure for the detection of antibody to B. abortus, B. melitensis, and B. suis.
Antibodies to Brucella canis, a rare cause of brucellosis, are not detected by this method. | | 23109 | BNP | B-Type Natriuretic Peptide | BNP, Brain-type Natriuretic peptide
| | | 26078 | BPSO | Bullous Pemphigoid, BP180 & BP230, IgG Antibodies, Serum (BPAB) | BP 180 BP 230 Bullous Pemphigoid | | | 25152 | BUP | Buprenorphine, Urine | Buprenex, Suboxone, Subutex, Temgesic
| | | 25374 | CO-BUP | Buprenorphine, Urine, Confirm Only by LCMS | Buprenex, Suboxone, Subutex, Temgesic
| | | 23249 | BUPRSO | Bupropion, Serum (178) | | |
|